Supporting the Production of Pharmaceuticals in Africa. (Bull World Health Organ 2016;94:71–72)
(2016; 2 pages)


Africa has more than 70% of the world’s people living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) and 90% of the world’s deaths due to malaria; noncommunicable diseases are also an increasing problem.4 The demand for safe, effective and affordable medicines is therefore great, but weak local pharmaceutical manufacturing capacity means that Africa largely depends on imported medicines. It is estimated that around 79% of all pharmaceuticals in Africa are imported. This significantly increases health expenditure and leaves people vulnerable to interruption of the supply of medicines. Access to life-saving medicines is a human right, but it remains far from being guaranteed for the majority of people living in Africa. Long lead times in international procurement, fragile logistics and storage capacity, and high transport and distribution costs hinder the broad access and affordability of essential medicines. Moreover, patented medicines for diseases like hepatitis, cancer and multidrug-resistant tuberculosis may be out of reach for many patients because of their high cost. Local production of quality-assured medicines is a critical strategy in the long term, in view of growing demands, as a way to ensure reliable access to affordable medicines.

Documents similaires
Le Portail d'information - Médicaments essentiels et produits de santé a été conçu et est maintenu par l'ONG Human Info. Dernière mise à jour: le 1 décembre 2019